StockData
20/20 Biolabs, Inc. logo

20/20 Biolabs, Inc. (AIDX) stock

AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/3059% below fair value
$0.20−0.02 (-9.38%)

Close on Nov 12, 2026Market cap $2.60MP/E –Yield –

20/20 Biolabs, Inc. grew revenue 16.7% to $2.05M over fiscal 2025. At the latest close the market valued the company at $2.60M.

Revenue
$2.05M
+16.7% vs. a year earlier
Operating income
-$3.33M
FY2025
EPS, diluted
-$0.76
FY2025

Key statistics

Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026

Valuation

Market cap
$2.60M
P/E ratio
–
Price to sales
1.27
Price to book
1.61
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$2.05M
Net income
-$3.74M
EPS, diluted
-$0.76
Book value per share
$0.15
Diluted shares
11M

Trading

Previous close
$0.22
Open
$0.22
Day's range
$0.19 – $0.22
Volume
246,932
Average volume (20 days)
249,904
RSI (14 days)
38.5
Volatility (1 year)
128.7%
Relative volume
5.78×

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.

PeriodAIDXS&P 500DifferenceAIDX per yearS&P 500 per year
1 month-44.3%-2.7%−41.6 pts
3 months-55.8%-1.7%−54.0 pts

Three years at a glance

Fiscal years 2023 to 2025, USD

Revenue

$2.05M+16.7% YoY

Gross profit

$604.54K+67.8% YoY

Operating income

-$3.33M

Net income

-$3.74M

EPS, diluted

-$0.76
Reported period

Press releases

Releases 20/20 Biolabs filed with the SEC as exhibits to Form 8-K or 6-K

  1. Investor Webinar NASDAQ: AIDX September 2, 2026
    Update
  2. PRESS RELEASE ISSUED ON AUGUST 17, 2026
    Results
  3. 8-K exhibit EX-99.1
    Update
  4. 8-K exhibit EX-99.1
    Update
  5. PRESS RELEASE ISSUED ON MAY 20, 2026
    Results
  6. PRESS RELEASE ISSUED ON MARCH 31, 2026
    Results

About 20/20 Biolabs

Services-Testing Laboratories

20/20 Biolabs, Inc. develops and commercializes artificial intelligence-powered, laboratory-based blood tests designed for the early detection and prevention of cancers and chronic diseases. The company offers two main diagnostic families under its OneTest brand: OneTest for Cancer, a multi-cancer early detection blood test based primarily on a panel of protein tumor markers, and OneTest for Longevity, which measures inflammatory biomarkers for wellness and longevity applications. In addition to clinical testing, the company operates a shared laboratory accelerator called CLIAx for overseas diagnostic start-ups seeking to enter the United States market, and maintains a legacy product line consisting of the BioCheck field test kit for screening suspicious powders for bioterror agents. Its customer base includes consumers, self-insured employers, and emergency responders such as firefighters.

Company profile, executives and history

20/20 Biolabs stock: common questions

What is 20/20 Biolabs's stock price?

AIDX closed at $0.20 on Nov 12, 2026, down 9.38% on the day.

What is 20/20 Biolabs's market cap?

20/20 Biolabs was worth $2.60M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.

What is AIDX's P/E ratio?

20/20 Biolabs lost money over fiscal 2025 (diluted EPS -$0.76), so it has no meaningful P/E ratio.

How much revenue does 20/20 Biolabs make?

20/20 Biolabs reported revenue of $2.05M for fiscal 2025, up 16.7% from a year earlier.

Does 20/20 Biolabs pay a dividend?

No. 20/20 Biolabs has not paid a cash dividend over the last twelve months.

How many AIDX shares are sold short?

0M shares were sold short at the latest FINRA report, 0.52% of the float, or 1.0 days of average trading volume.

Who are 20/20 Biolabs's competitors?

Companies most similar to 20/20 Biolabs by business, industry and size include BIAF, ABSI, ONMD, VNRX, IMDX.

See a number that looks wrong?